Traders Buy Shares of Edwards Lifesciences Corporation (EW) on Weakness

Investors purchased shares of Edwards Lifesciences Corporation (NYSE:EW) on weakness during trading on Tuesday. $47.68 million flowed into the stock on the tick-up and $19.32 million flowed out of the stock on the tick-down, for a money net flow of $28.36 million into the stock. Of all stocks tracked, Edwards Lifesciences Corporation had the 14th highest net in-flow for the day. Edwards Lifesciences Corporation traded down ($0.27) for the day and closed at $109.95

A number of equities analysts have commented on the stock. BidaskClub cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Canaccord Genuity reissued a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. Cowen and Company reissued an “outperform” rating and issued a $135.00 price target (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation boosted their price target on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $120.75.

The company has a market capitalization of $23.22 billion, a price-to-earnings ratio of 33.35 and a beta of 0.62. The company has a 50-day moving average of $111.81 and a 200 day moving average of $111.14.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.76 earnings per share. Equities research analysts predict that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

In related news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $114.80, for a total value of $3,776,920.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Insiders have sold 182,201 shares of company stock valued at $20,768,154 over the last three months. Insiders own 2.13% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. ETF Managers Group LLC bought a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $112,000. Shine Investment Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $126,000. Cornerstone Advisors Inc. raised its holdings in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 219 shares in the last quarter. Alexandria Capital LLC raised its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares in the last quarter. Finally, MPS Loria Financial Planne

A number of equities analysts have commented on the stock. BidaskClub cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Canaccord Genuity reissued a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. Cowen and Company reissued an “outperform” rating and issued a $135.00 price target (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation boosted their price target on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $120.75.

The company has a market capitalization of $23.22 billion, a price-to-earnings ratio of 33.35 and a beta of 0.62. The company has a 50-day moving average of $111.81 and a 200 day moving average of $111.14.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.76 earnings per share. Equities research analysts predict that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

In related news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $114.80, for a total value of $3,776,920.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Insiders have sold 182,201 shares of company stock valued at $20,768,154 over the last three months. Insiders own 2.13% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. ETF Managers Group LLC bought a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $112,000. Shine Investment Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $126,000. Cornerstone Advisors Inc. raised its holdings in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 219 shares in the last quarter. Alexandria Capital LLC raised its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares in the last quarter. Finally, MPS Loria Financial Planners LLC bought a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $140,000. Hedge funds and other institutional investors own 82.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Traders Buy Shares of Edwards Lifesciences Corporation (EW) on Weakness” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://ledgergazette.com/2017/10/10/traders-buy-shares-of-edwards-lifesciences-corporation-ew-on-weakness.html.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply